Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Donepezil Hydrochloride

FDA-approved product (tablet, oral), marketed as Adlarity, Aricept, Aricept Odt and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Donepezil Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alzheimer disease
  • Dementia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anticholinesterases
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Donepezil Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Donepezil Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phenserine on the Alzheimer's Treatment Horizon, Study 1

    NCT06774261 · start 2025-02-01

    Registered record
    Registry ID
    NCT06774261
    Conditions
    Alzheimer Disease; Mild Cognitive Impairment
    Interventions
    Phenserine; Donepezil (Aricept®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-02-01
    Completion
    2025-12-08
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Mild Cognitive Impairment
    InterventionPhenserine; Donepezil (Aricept®)
    PhasePhase 1
    Registry statusCompleted

  • Acetylcholinesterase Inhibitor in Anorexia Nervosa: Multicenter, Double-Blind, Placebo-Controlled Trial

    NCT06687993 · start 2024-11

    Registered record
    Registry ID
    NCT06687993
    Conditions
    Anorexia Nervosa Restricting Type
    Interventions
    Donepezil 2.5 mg; Donepezil 5 mg; Placebo Comparator
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-11
    Completion
    2030-05
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnorexia Nervosa Restricting Type
    InterventionDonepezil 2.5 mg; Donepezil 5 mg; Placebo Comparator
    PhasePhase 2
    Registry statusNot yet recruiting

  • Effect of Donepezil on Speech Recognition in Cochlear Implant Users

    NCT05438264 · start 2023-03-10

    Registered record
    Registry ID
    NCT05438264
    Conditions
    Bilateral Sensorineural Hearing Loss
    Interventions
    Donepezil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Active not recruiting
    Start
    2023-03-10
    Completion
    2026-09-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBilateral Sensorineural Hearing Loss
    InterventionDonepezil; Placebo
    PhaseEarly phase 1
    Registry statusActive not recruiting

  • Technical R&D and Demonstration of Intelligent Medical Care in Alzheimer's Disease's Management

    NCT05641480 · start 2022-06-03

    Registered record
    Registry ID
    NCT05641480
    Conditions
    Alzheimer Disease; Subjective Cognitive Decline; Mild Cognitive Impairment; Mild Dementia
    Interventions
    Transcutaneous electrical acupoint stimulation&Music therapy; Donepezil hydrochloride tablets or carpalatine bitartrate tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-06-03
    Completion
    2025-12-09
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Subjective Cognitive Decline; Mild Cognitive Impairment; Mild Dementia
    InterventionTranscutaneous electrical acupoint stimulation&Music therapy; Donepezil hydrochloride tablets or carpalatine bitartrate tablets
    PhaseNot applicable
    Registry statusUnknown

  • Effects of Acetylcholine and Attention on Visual Spatial Representations in the Brain

    NCT05003063 · start 2021-02-04

    Registered record
    Registry ID
    NCT05003063
    Conditions
    Visual Perception; Attention; Information Processing; Cholinergic System
    Interventions
    Donepzil; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2021-02-04
    Completion
    2021-08-02
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisual Perception; Attention; Information Processing; Cholinergic System
    InterventionDonepzil; Placebo oral tablet
    PhaseEarly phase 1
    Registry statusCompleted

  • Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

    NCT04617782 · start 2020-12-08

    Registered record
    Registry ID
    NCT04617782
    Conditions
    Healthy Subjects
    Interventions
    Donepezil TDS; Aricept
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-12-08
    Completion
    2021-04-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionDonepezil TDS; Aricept
    PhasePhase 1
    Registry statusCompleted

  • The Effect of Donepezil on Wound Healing

    NCT04505670 · start 2020-08-30

    Registered record
    Registry ID
    NCT04505670
    Conditions
    Wound Heal
    Interventions
    Donepezil; Placebo oral tablet; Topical Zinc Oxide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-08-30
    Completion
    2023-07-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWound Heal
    InterventionDonepezil; Placebo oral tablet; Topical Zinc Oxide
    PhasePhase 2
    Registry statusUnknown

  • Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

    NCT03599726 · start 2018-07-30

    Registered record
    Registry ID
    NCT03599726
    Conditions
    Parkinson Disease
    Interventions
    Donepezil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-07-30
    Completion
    2019-07-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionDonepezil; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • Donepezil, Residual Excessive Daytime Sleepiness, Obstructive Sleep Apnea

    NCT03299257 · start 2018-07-06

    Registered record
    Registry ID
    NCT03299257
    Conditions
    OSA; Sleepiness
    Interventions
    donepezil treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-07-06
    Completion
    2019-03-02
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOSA; Sleepiness
    Interventiondonepezil treatment
    PhasePhase 4
    Registry statusUnknown

  • CKD-355 Drug-drug Interaction Study (CKD-355 DDI P1)

    NCT03569579 · start 2018-04-16

    Registered record
    Registry ID
    NCT03569579
    Conditions
    Central Nervous System Diseases
    Interventions
    Memantine Tab. 10mg; Memantine Tab. 10mg + Donepezil Tab. 10mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-04-16
    Completion
    2018-06-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Nervous System Diseases
    InterventionMemantine Tab. 10mg; Memantine Tab. 10mg + Donepezil Tab. 10mg
    PhasePhase 1
    Registry statusCompleted

  • A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

    NCT03397862 · start 2017-11-14

    Registered record
    Registry ID
    NCT03397862
    Conditions
    Skin Irritation; Sensitization
    Interventions
    Donepezil TDS; Vehicle TDS
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-11-14
    Completion
    2018-04-02
    Enrolment
    256

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Irritation; Sensitization
    InterventionDonepezil TDS; Vehicle TDS
    PhasePhase 1
    Registry statusCompleted

  • A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease

    NCT03197740 · start 2017-10-12

    Registered record
    Registry ID
    NCT03197740
    Conditions
    Alzheimer Disease
    Interventions
    Donepezil patch; aricept Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-10-12
    Completion
    2020-07-20
    Enrolment
    399

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionDonepezil patch; aricept Tab
    PhasePhase 3
    Registry statusCompleted

  • Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients

    NCT03184467 · start 2017-09-05

    Registered record
    Registry ID
    NCT03184467
    Conditions
    Alzheimer Disease
    Interventions
    Normal Saline 0.9%; GV1001 0.56 mg; GV1001 1.12 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-09-05
    Completion
    2019-09-19
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionNormal Saline 0.9%; GV1001 0.56 mg; GV1001 1.12 mg
    PhasePhase 2
    Registry statusCompleted

  • A Retrospective Study to Investigate the Additive Effectiveness of Chinese Herbal Medicine in Alzheimer's Disease

    NCT03221894 · start 2017-07-15

    Registered record
    Registry ID
    NCT03221894
    Conditions
    Alzheimer Disease
    Interventions
    GRAPE granules
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-07-15
    Completion
    2021-07-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionGRAPE granules
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease

    NCT02787746 · start 2016-04

    Registered record
    Registry ID
    NCT02787746
    Conditions
    Alzheimer's Disease
    Interventions
    Donepezil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-04
    Completion
    2019-03
    Enrolment
    241

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionDonepezil
    PhasePhase 4
    Registry statusCompleted